Atossa Therapeutics (NASDAQ:ATOS - Free Report) had its target price lifted by Ascendiant Capital Markets from $7.00 to $7.25 in a research note released on Monday morning,Benzinga reports. They currently have a buy rating on the stock. Ascendiant Capital Markets also issued estimates for Atossa Therapeutics' Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS and Q4 2026 earnings at ($0.06) EPS.
Separately, HC Wainwright reissued a "buy" rating and set a $7.00 target price on shares of Atossa Therapeutics in a research note on Wednesday, March 26th.
Read Our Latest Analysis on Atossa Therapeutics
Atossa Therapeutics Price Performance
ATOS traded down $0.01 during trading on Monday, hitting $0.73. The stock had a trading volume of 609,428 shares, compared to its average volume of 830,525. The company has a 50 day moving average price of $0.70 and a 200-day moving average price of $0.99. Atossa Therapeutics has a one year low of $0.55 and a one year high of $1.81. The firm has a market cap of $94.63 million, a price-to-earnings ratio of -3.33 and a beta of 1.46.
Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last announced its quarterly earnings data on Tuesday, March 25th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. As a group, sell-side analysts predict that Atossa Therapeutics will post -0.22 EPS for the current fiscal year.
Institutional Trading of Atossa Therapeutics
A number of institutional investors have recently modified their holdings of ATOS. Gallagher Capital Advisors LLC purchased a new stake in shares of Atossa Therapeutics in the 4th quarter valued at about $25,000. Millennium Management LLC purchased a new position in shares of Atossa Therapeutics in the fourth quarter valued at about $28,000. Two Sigma Advisers LP raised its position in Atossa Therapeutics by 214.1% during the 4th quarter. Two Sigma Advisers LP now owns 42,400 shares of the company's stock valued at $40,000 after purchasing an additional 28,900 shares during the last quarter. Intech Investment Management LLC lifted its stake in Atossa Therapeutics by 224.0% in the fourth quarter. Intech Investment Management LLC now owns 62,844 shares of the company's stock worth $59,000 after acquiring an additional 43,449 shares during the period. Finally, Wells Fargo & Company MN lifted its position in shares of Atossa Therapeutics by 30.7% in the 4th quarter. Wells Fargo & Company MN now owns 71,720 shares of the company's stock worth $68,000 after purchasing an additional 16,853 shares during the period. 12.74% of the stock is currently owned by hedge funds and other institutional investors.
Atossa Therapeutics Company Profile
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
See Also
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
